Literature DB >> 32381277

Epigenetic Modifications in Schizophrenia and Related Disorders: Molecular Scars of Environmental Exposures and Source of Phenotypic Variability.

Juliet Richetto1, Urs Meyer2.   

Abstract

Epigenetic modifications are increasingly recognized to play a role in the etiology and pathophysiology of schizophrenia and other psychiatric disorders with developmental origins. Here, we summarize clinical and preclinical findings of epigenetic alterations in schizophrenia and relevant disease models and discuss their putative origin. Recent findings suggest that certain schizophrenia risk loci can influence stochastic variation in gene expression through epigenetic processes, highlighting the intricate interaction between genetic and epigenetic control of neurodevelopmental trajectories. In addition, a substantial portion of epigenetic alterations in schizophrenia and related disorders may be acquired through environmental factors and may be manifested as molecular "scars." Some of these scars can influence brain functions throughout the entire lifespan and may even be transmitted across generations via epigenetic germline inheritance. Epigenetic modifications, whether caused by genetic or environmental factors, are plausible molecular sources of phenotypic heterogeneity and offer a target for therapeutic interventions. The further elucidation of epigenetic modifications thus may increase our knowledge regarding schizophrenia's heterogeneous etiology and pathophysiology and, in the long term, may advance personalized treatments through the use of biomarker-guided epigenetic interventions.
Copyright © 2020 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA methylation; Early-life adversity; Gene–environment interactions; Histone modification; Noncoding RNA; Psychosis

Mesh:

Year:  2020        PMID: 32381277     DOI: 10.1016/j.biopsych.2020.03.008

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  22 in total

1.  Schizophrenia-derived hiPSC brain microvascular endothelial-like cells show impairments in angiogenesis and blood-brain barrier function.

Authors:  Bárbara S Casas; Gabriela Vitória; Catalina P Prieto; Mariana Casas; Carlos Chacón; Markus Uhrig; Fernando Ezquer; Marcelo Ezquer; Stevens K Rehen; Verónica Palma
Journal:  Mol Psychiatry       Date:  2022-06-15       Impact factor: 15.992

2.  MiR-574-5P, miR-1827, and miR-4429 as Potential Biomarkers for Schizophrenia.

Authors:  Omran Davarinejad; Sajad Najafi; Hossein Zhaleh; Farzaneh Golmohammadi; Farnaz Radmehr; Mostafa Alikhani; Reza Heidari Moghadam; Yazdan Rahmati
Journal:  J Mol Neurosci       Date:  2021-11-22       Impact factor: 3.444

3.  Effect of Integrated Psychobehavioral Care on Emotional-Behavioral Responses, Cognitive Changes in Outpatients with Schizophrenia Followed Up: Based on a Prospective Randomized Controlled Study.

Authors:  Yao Yao; Yali Xu; Hongyan Guo; Kunxiu Han; Zhuo Dai
Journal:  Comput Math Methods Med       Date:  2022-06-16       Impact factor: 2.809

4.  Subtypes of schizophrenia identified by multi-omic measures associated with dysregulated immune function.

Authors:  Chunyan Luo; XueNan Pi; Na Hu; Xiao Wang; Yuan Xiao; Siyi Li; John A Sweeney; Jeffrey R Bishop; Qiyong Gong; Dan Xie; Su Lui
Journal:  Mol Psychiatry       Date:  2021-09-29       Impact factor: 15.992

Review 5.  Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives.

Authors:  Evgeny A Ermakov; Elena M Dmitrieva; Daria A Parshukova; Daria V Kazantseva; Alisa R Vasilieva; Liudmila P Smirnova
Journal:  Oxid Med Cell Longev       Date:  2021-01-23       Impact factor: 6.543

6.  LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models.

Authors:  Rina Baba; Satoru Matsuda; Yuuichi Arakawa; Ryuji Yamada; Noriko Suzuki; Tatsuya Ando; Hideyuki Oki; Shigeru Igaki; Masaki Daini; Yasushi Hattori; Shigemitsu Matsumoto; Mitsuhiro Ito; Atsushi Nakatani; Haruhide Kimura
Journal:  Sci Adv       Date:  2021-03-12       Impact factor: 14.136

7.  Clinical Correlates of the NR3C1 Gene Methylation at Various Stages of Psychosis.

Authors:  Błażej Misiak; Jerzy Samochowiec; Anna Konopka; Barbara Gawrońska-Szklarz; Jan Aleksander Beszłej; Elżbieta Szmida; Paweł Karpiński
Journal:  Int J Neuropsychopharmacol       Date:  2021-04-21       Impact factor: 5.176

8.  Identification of inflammatory subgroups of schizophrenia and bipolar disorder patients with HERV-W ENV antigenemia by unsupervised cluster analysis.

Authors:  Ryad Tamouza; Urs Meyer; Marianne Foiselle; Jean-Romain Richard; Ching-Lieng Lu; Wahid Boukouaci; Philippe Le Corvoisier; Caroline Barrau; Alexandre Lucas; Hervé Perron; Marion Leboyer
Journal:  Transl Psychiatry       Date:  2021-07-06       Impact factor: 6.222

Review 9.  Looking at Intergenerational Risk Factors in Schizophrenia Spectrum Disorders: New Frontiers for Early Vulnerability Identification?

Authors:  Michele Poletti; Eva Gebhardt; Lorenzo Pelizza; Antonio Preti; Andrea Raballo
Journal:  Front Psychiatry       Date:  2020-10-23       Impact factor: 4.157

Review 10.  Epigenomic Dysregulation in Schizophrenia: In Search of Disease Etiology and Biomarkers.

Authors:  Behnaz Khavari; Murray J Cairns
Journal:  Cells       Date:  2020-08-05       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.